121 related articles for article (PubMed ID: 14751142)
1. Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression.
Murthi P; Barker G; Nowell CJ; Rice GE; Baker MS; Kalionis B; Quinn MA
Gynecol Oncol; 2004 Jan; 92(1):80-8. PubMed ID: 14751142
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
3. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
[TBL] [Abstract][Full Text] [Related]
4. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
5. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
6. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma.
Moser TL; Young TN; Rodriguez GC; Pizzo SV; Bast RC; Stack MS
Int J Cancer; 1994 Feb; 56(4):552-9. PubMed ID: 8112891
[TBL] [Abstract][Full Text] [Related]
7. Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer.
Ahmed N; Pansino F; Baker M; Rice G; Quinn M
J Cell Biochem; 2002; 84(4):675-86. PubMed ID: 11835393
[TBL] [Abstract][Full Text] [Related]
8. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
9. Analyses of matrix metalloproteinases and their inhibitors in cyst fluid of serous ovarian tumors.
Furuya M; Ishikura H; Ogawa Y; Kawarada Y; Shibata M; Fujimoto S; Yoshiki T
Pathobiology; 2000; 68(6):239-44. PubMed ID: 11493755
[TBL] [Abstract][Full Text] [Related]
10. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles.
Graves LE; Ariztia EV; Navari JR; Matzel HJ; Stack MS; Fishman DA
Cancer Res; 2004 Oct; 64(19):7045-9. PubMed ID: 15466198
[TBL] [Abstract][Full Text] [Related]
11. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
Borgfeldt C; Bendahl PO; Gustavsson B; Långström E; Fernö M; Willén R; Grenman S; Casslén B
Int J Cancer; 2003 Nov; 107(4):658-65. PubMed ID: 14520707
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade.
Ahmed N; Pansino F; Clyde R; Murthi P; Quinn MA; Rice GE; Agrez MV; Mok S; Baker MS
Carcinogenesis; 2002 Feb; 23(2):237-44. PubMed ID: 11872628
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells.
Choi JH; Choi KC; Auersperg N; Leung PC
Cancer Res; 2006 Apr; 66(7):3912-20. PubMed ID: 16585220
[TBL] [Abstract][Full Text] [Related]
14. Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression.
Behrens P; Rothe M; Florin A; Wellmann A; Wernert N
Int J Mol Med; 2001 Aug; 8(2):149-54. PubMed ID: 11445865
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.
Furuya M; Ishikura H; Kawarada Y; Ogawa Y; Sakuragi N; Fujimoto S; Yoshiki T
Gynecol Oncol; 2000 Aug; 78(2):106-12. PubMed ID: 10926788
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract][Full Text] [Related]
17. Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells.
Miyagi E; Yasumitsu H; Hirahara F; Minaguchi H; Koshikawa N; Miyazaki K; Umeda M
Jpn J Cancer Res; 1995 Jun; 86(6):568-76. PubMed ID: 7622422
[TBL] [Abstract][Full Text] [Related]
18. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1).
Borgfeldt C; Hansson SR; Gustavsson B; Måsbäck A; Casslén B
Int J Cancer; 2001 May; 92(4):497-502. PubMed ID: 11304683
[TBL] [Abstract][Full Text] [Related]
19. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
